ArticleJournal of magnetic resonance imaging : JMRI2026
Prognostic Value of MRI-Based Treatment Response Assessment Criteria in Hepatocellular Carcinoma After Stereotactic Body Radiotherapy: A Comparative Analysis of mRECIST, LI-RADS TRA Version 2017, and LI-RADS Radiation TRA Version 2024.
Article in Journal of magnetic resonance imaging : JMRI, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Editorial for "Prognostic Value of MRI-Based Treatment Response Assessment Criteria in Hepatocellular Carcinoma After Stereotactic Body Radiotherapy: A Comparative Analysis of mRECIST, LI-RADS TRA Version 2017, and LI-RADS Radiation TRA Version 2024".Journal of magnetic resonance imaging : JMRI · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAccurate imaging assessment of hepatocellular carcinoma (HCC) after stereotactic body radiotherapy (SBRT) remains challenging. Although LI-RADS CT/MRI Radiation Treatment Response Assessment (TRA v2024) was developed for this purpose, its prognostic value for survival stratification after SBRT remains to be validated. PURPOSE: To compare the prognostic performance of mid-term (3-6 months) and late-term (9-12 months) MRI-based treatment response assessed using modified RECIST (mRECIST), LI-RADS TRA v2017, and LI-RADS Radiation TRA v2024 in patients with HCC. STUDY TYPE: Retrospective cohort study. POPULATION: 125 patients with HCC underwent SBRT (111 males; mean age, 56.4 ± 10.8 years). FIELD STRENGTH/SEQUENCE: 3.0 T; axial fat-suppressed fast spin-echo T2-weighted imaging, diffusion-weighted imaging, pre-contrast gradient recalled echo T1-weighted imaging, and contrast-enhanced late arterial phase, portal venous phase, and delayed/transitional phase. ASSESSMENT: Tumor response was independently evaluated by three radiologists using three treatment assessment methods. Ancillary features (AFs) were additionally recorded to assess their incremental prognostic value. Overall survival (OS) and progression-free survival (PFS) were analyzed according to response categories. STATISTICAL TESTS: Kolmogorov-Smirnov test, Intraclass correlation coefficients, Cohen's κ, Variance inflation factor analysis, Kaplan-Meier method, Log-rank tests with Bonferroni correction, Univariate and multivariable Cox regression analyses. Statistical significance was defined as p < 0.05.
resultsAt mid-term follow-up, LI-RADS Radiation TRA v2024 showed greater discrimination for PFS than mRECIST and LI-RADS TRA v2017, with no OS difference (p > 0.999). Across all three criteria, late-term response assessment yielded better prognostic stratification for PFS and OS than did mid-term evaluation. At the late-term follow-up, LI-RADS Radiation TRA v2024 was strongly associated with OS (HR = 15.80, 95% CI: 3.34-75.00) and PFS (HR = 6.31, 95% CI: 2.68-14.90). Adding AFs provided no further prognostic improvement. DATA
conclusionLI-RADS Radiation TRA v2024 demonstrates strong prognostic stratification after SBRT, particularly at late-term MRI evaluation. EVIDENCE LEVEL: 3. TECHNICAL EFFICACY: Stage 2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.